electroCore (ECOR)

• Market cap: $54.5M
• 1 day: 0.26%
• 5 days: 25.75%
• 1 month: 4.56%
• 3 months: -54.09%
• 6 months: -33.48%
• Year to date: -54.86%
• 1 year: 33.98%
• 5 years: -51.88%
• 10 years: -97.46%
• Sector: Healthcare
• Industry: Medical Devices

About: electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Employees: 62

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

101% more capital invested

Capital invested by funds: $7.15M [Q3] → $14.4M (+$7.25M) [Q4]

39% more funds holding

Funds holding: 23 [Q3] → 32 (+9) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

9.97% less ownership

Funds ownership: 23.49% [Q3] → 13.52% (-9.97%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $25 230% upside
• Avg. target: $26 237% upside
• High target: $26 243% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Ladenburg Thalmann Jeffrey Cohen 0% 1-year accuracy 0 / 1 met price target	243% upside $26	Buy Maintained	13 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth 28% 1-year accuracy 54 / 192 met price target	230% upside $25	Buy Reiterated	13 Mar 2025